R&D revolution for drugs could secure good, affordable prices
This article was originally published in SRA
Executive Summary
Drug companies that want to offer payers a more attractive price to secure market access for their new innovations should try a whole new approach to R&D. Step away from the randomized control trial (RCT), consult with patients and exploit data already out there, says Stuart Dollow, chief executive and founder of Vermilion Life Sciences, and you could potentially afford more flexibility on price.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.